Drugs in the Pipeline
MK-2060 is an investigational monoclonal antibody designed to inhibit the activation of Factor XI and its ability to activate downstream proteins.
Uncertainty regarding diuretic efficacy and optimal dosing in hemodialysis likely contributes to practice variation, according to investigators.
A list of contraindications and drug interactions for HIV medications.
Study findings do not support initiation of uric acid-lowering therapy to prevent CKD.
This study raises important questions about the choice between lactated Ringer and saline.
Study findings highlight an "unmet need" for newer therapies.
Affordability of SGLT2i may contribute to the low prescription rate in CKD.
Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.
Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.